BofA warns Fed risks policy mistake with early rate cuts
Director Bethany Sensenig of Supernus Pharmaceuticals (NASDAQ:SUPN), sold 5,369 shares of common stock on August 14, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week high of $43.62, having delivered a strong 23.6% return over the past year. The shares were sold at a weighted average price of $42.25, resulting in a total transaction value of $226,840.
The prices for the shares sold ranged from $41.88 to $42.52. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on May 15, 2025. Following the transaction, Sensenig directly owns zero shares of Supernus Pharmaceuticals.
In other recent news, Supernus Pharmaceuticals reported its second-quarter 2025 earnings, showcasing a mixed financial performance. The company achieved revenue of $165 million, surpassing analysts’ consensus estimates of $154.3 million. This revenue growth was primarily driven by strong performance from its Qelbree and Gocovri products. However, Supernus’s earnings per share (EPS) fell short, coming in at $0.40 compared to the expected $0.48. In light of these results, Stifel raised its price target for Supernus Pharmaceuticals from $38 to $43, while maintaining a Hold rating on the stock. The firm’s decision reflects confidence in the company’s revenue growth despite the EPS miss. These developments highlight the ongoing market interest in Supernus Pharmaceuticals’ product performance and financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.